Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Function impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify therapeutic efficacy of statins in a population based cohort
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2719931
Author(s) Meyer zu Schwabedissen, H. E.; Albers, M.; Baumeister, S. E.; Rimmbach, C.; Nauck, M.; Siegmund, W.; Voelzke, H.; Kromer, H. K.
Author(s) at UniBasel Meyer zu Schwabedissen, Henriette
Year 2015
Title Function impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify therapeutic efficacy of statins in a population based cohort
Journal Pharmacogenetics and genomics
Volume 25
Number 1
Pages / Article-Number 8-18
Keywords drug efficacy, hypercholesterolaemia, OATP1B1, statins
Mesh terms Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease, pathology; Fatty Acids, Monounsaturated, administration & dosage; Female; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors, administration & dosage; Indoles, administration & dosage; Lipid Metabolism, genetics; Lovastatin, genetics; Male; Middle Aged; Organic Anion Transporters, genetics; Pravastatin, genetics; Risk Assessment; Simvastatin, administration & dosage; Solute Carrier Organic Anion Transporter Family Member 1b1
Abstract BackgroundThe efficacy of statins, which are used commonly in primary and secondary prevention of cardiovascular diseases, shows a wide range of interindividual variability. Genetic variants of OATP1B1, a hepatic uptake transporter, can modify access of statins to its therapeutic target, thereby potentially altering drug efficacy. We studied the impact of genetic variants of OATP1B1 on the lipid-lowering efficacy of statins in a population-based setting.Materials and methodsThe basis of the analysis was the Study of Health in Pomerania, a cohort of 2732 men and women aged 20-81 years. Included in the statistical analysis to evaluate the impact of OATP1B1 on therapeutic efficacy of statins were 214 individuals diagnosed with dyslipidaemia during initial recruitment and receiving statins during the 5-year follow-up.ResultsAnalysing the impact of the OATP1B1 genotype, we observed a trend for lower statin-induced total cholesterol reduction in carriers of the SLCO1B1 512C variant. Restricting the analysis to patients receiving simvastatin, pravastatin, lovastatin and fluvastatin indicated a statistically significant association of the OATP1B1 genotype on lipid parameters at the 5-year follow-up. No such effect was observed for atorvastatin. Calculation of achievement of treatment goals according to the NCEP-ATPIII guidelines showed a lower rate of successful treatment when harbouring the mutant allele for patients taking simvastatin (46.7 vs. 73.9%). A similar trend was observed for pravastatin (34.4 vs. 70.4%).ConclusionGenetic variants of OATP1B1 leading to impaired hepatic uptake of statins translated into reduced drug efficacy in a population-based cohort. (C) 2014 Wolters Kluwer Health vertical bar Williams & Wilkins.
Publisher Lippincott Williams & Wilkins
ISSN/ISBN 1744-6872
edoc-URL http://edoc.unibas.ch/dok/A6337453
Full Text on edoc Available
Digital Object Identifier DOI 10.1097/FPC.0000000000000098
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/25379722
ISI-Number WOS:000346632900002
Document type (ISI) Article
 
   

MCSS v5.8 PRO. 0.327 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
30/05/2024